Technology
Health
Pharmaceutical

Assembly Biosciences

$19.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.15 (-5.78%) Today
+$0.87 (4.64%) After Hours

Why Robinhood?

You can buy or sell ASMB and other stocks, options, ETFs, and crypto commission-free!

About

Assembly Biosciences, Inc. Common Stock, also called Assembly Biosciences, is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. Read More It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Employees
95
Headquarters
Carmel, Indiana
Founded
2005
Market Cap
506.85M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
219.46K
High Today
$19.84
Low Today
$18.65
Open Price
$19.84
Volume
62.77K
52 Week High
$63.16
52 Week Low
$17.71

Collections

Technology
Health
Pharmaceutical
Biotechnology
Therapy
US
North America

News

Seeking AlphaFeb 28

Assembly Biosciences misses by $0.08, revenue in-line - Assembly Biosciences, Inc. (NASDAQ:ASMB)

26
Markets InsiderFeb 28

Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results

SAN FRANCISCO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the fourth quarter and year ended December 31, 2018. “Assembly has achieved many significant milestones over the past year across both our HBV and microbiome programs,” stated Derek Small, President and Chief Executive Officer ...

6
MarketBeatFeb 22

Stock Price, News, & Analysis for Assembly Biosciences

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a plat...

0

Earnings

-$1.30
-$0.90
-$0.51
-$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.